AstraZeneca’s Truqap, Faslodex combo recommended for EU approval for breast cancer treatment
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) for approval within ... Read More
FDA approves AstraZeneca’s Truqap for advanced breast cancer treatment
In a notable development in the field of oncology, the US Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap (capivasertib) in combination with Faslodex ... Read More